Wednesday, February 10, 2010, 2:39PM AEST - The Australian Stockmarket closes in 1 hour and 26 minutes.
To create a watchlist or portfolio of shares, Register

Aradigm Corp. (ARDM.OB)

7:13AM AEST: 0.1375 USD  Down 0.0025 (1.79%)  
 MORE ON ARDM.OB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARADIGM CORP (OTC BB:ARDM.OB) Delayed quote dataEdit
Last Trade:0.1375 USD
Trade Time: 7:13AM AEST
Change:Down 0.0025 (1.79%)
Prev Close:0.14
Open:0.14
Bid:0.133 x 5000
Ask:0.14 x 5000
1y Target Est:2.25
Day's Range:0.13 - 0.14
52wk Range:0.07 - 0.37
Volume:46,890
Avg Vol (3m):223,465
Market Cap:14.08M
P/E (ttm):N/A
EPS (ttm):-0.194
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ARDM.OB to Portfolio   Download Data

 HEADLINES 
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Business Wire (Thu, Feb 4)
Aradigm to Present at Biotech Showcase 2010 on January 12
Business Wire (Wed, Jan 6)
Aradigm Lippert/Heilshorn Life Sciences Call scheduled for 12:00 pm ET today
Vcall (Wed, Dec 16)
Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15
Business Wire (Thu, Dec 10)
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Business Wire (Mon, Nov 16)
ARADIGM CORP Financials
EDGAR Online Financials (Sat, Nov 14)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
Emerging Stock Report Initiates Independent Research Coverage On Aradigm Corp.
GlobeNewswire (Wed, Sep 9)
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Aug 7)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Aug 7)
More Headlines for ARDM.OB...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.14
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices